GlassScriptPhysician profile
Randy Allan Jordan
NPI 1780695312
$3,636.94
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $359 · 2021: $605 · 2022: $608 · 2023: $908 · 2024: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,568.47 | 2019-2024 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.62 | 2019-2024 | Jardiance |
| Pfizer INC. | $274.38 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $236.36 | 2019-2023 | Xarelto |
| Amgen INC. | $210.27 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $190.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $141.47 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $97.73 | 2019-2023 | Eliquis |
| Irhythm Technologies, INC. | $88.89 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $84.17 | 2019-2024 | Onpattro, Amvuttra |
| United Therapeutics Corporation | $82.28 | 2023-2024 | Orenitram, Tyvaso, Remodulin |
| Merck Sharp & Dohme LLC | $80.94 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $49.64 | 2019-2023 | Watchman Access System |
| Scpharmaceuticals INC. | $35.69 | 2023-2024 | |
| Esperion Therapeutics, INC. | $30.01 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.23 | 2021 | |
| Akcea Therapeutics, INC. | $16.12 | 2019 | |
| Philips North America LLC | $15.66 | 2024 | (Ck7) Extended Holter |
| Novo Nordisk INC | $15.06 | 2023 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $14.78 | 2024 | Arcalyst |
| Cmp Pharma, INC. | $14.22 | 2023 | Carospir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.74 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.52 | 2023 | Inpefa |
| Gilead Sciences, INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.